ulcerative colitis semaglutide Patients with stable inflammatory bowel disease (IBD) and comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse Semaglutide and Ulcerative Colitis: Safety

Theres the suddenly unrecognizable boss, a colleague who crash-injects GLP-1s to get bikini-ready for vacations, the slimmed-down gym buddy whose doctor husband is reportedly slipping her scripts, and countless Facebook friends who seem slimmer each time we log on

While many weight loss medications may target body fat in an attempt to burn it faster, controlling calorie consumption is also an effective way of promoting weight loss

The average plateau arrival at 43.2 weeks brings total weight loss to 22 to 24% of starting weight

Does it work by reducing inflammation or modulating pain

Both are administered as subcutaneous injections, typically once daily

References: Drugscom